Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99.
Serenella Eppenberger-CastoriDirk KlingbielThomas RuhstallerDaniel DietrichDaniel Alexander RufleKarin RothgiesserOlivia PaganiBeat ThürlimannPublished in: BMC cancer (2020)
Registration Number by ClinicalTrials.gov: NCT00004935, Trial number: SAKK22/99. Registered on 27 January 2003.